Clinical trials: Insufficient Metabolic Control
Type 2 Diabetes
Dapagliflozin DPPIV Inhibitor add-on Study
This study aims to investigate how dapagliflozin can control blood sugar in patients with type 2 diabetes when added to existing treatments (sitagliptin alone or in combination with metformin).
- Trial name
- NCT00984867
- Testing
- Dapagliflozin
- Where
- 88 sites in United States, Argentina and 4 more
- Volunteers
- 833 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
This is a multi-center, randomised, double-blind, placebo-controlled, parallel-group, efficacy and safety study of empagliflozin as add-on to insulin in Japanese patients with Type 2 Diabetes Mellitus with insufficient glycaemic…
- Trial name
- NCT02589639
- Testing
- Empagliflozin
- Where
- 48 sites in Japan
- Volunteers
- 269 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Test How Well Empagliflozin Works in Chinese Patients With Type 2 Diabetes Who Already Take Insulin
This is a study in Chinese adults with type 2 diabetes. The study is open to people who take insulin but still have too high blood sugar levels. Participants may additionally be taking up to 2 other medicines for their diabetes.
- Trial name
- NCT04233801
- Testing
- Empagliflozin
- Where
- 24 sites in China
- Volunteers
- 219 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes, High Blood Sugar
Evaluate Safety as Mono or Combination Therapies With Anti-diabetes Mellitus Drugs in Japanese Subjects With Type 2 Diabetes Mellitus
This is a long term, single arm, open label study to evaluate the safety and efficacy of dapagliflozin as monotherapy or in combination therapy with other anti diabetic drug in Japanese subjects with type 2 diabetes mellitus who…
- Trial name
- NCT01294436
- Testing
- Dapagliflozin
- Where
- 38 sites in Japan
- Volunteers
- 728 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).
This is an efficacy and safety study of ertugliflozin in participants with type 2 diabetes mellitus (T2DM) and inadequate glycemic control on metformin monotherapy.
- Trial name
- NCT02033889
- Testing
- Ertugliflozin 5 mg, Ertugliflozin 15 mg, Glimepiride
- Volunteers
- 621 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
A 16 Weeks Study on Efficacy and Safety of Two Doses of Empagliflozin (BI 10773) (Once Daily Versus Twice Daily) in Patients With Type 2 Diabetes Mellitus and Preexisting Metformin Therapy
The aim of this study is to investigate the efficacy and safety of two doses (high and low) of empagliflozin as add-on therapy to metformin in patients with type 2 diabetes mellitus (T2DM) and insufficient glycaemic control.
- Trial name
- NCT01649297
- Testing
- empagliflozin (low dose qd), Empagliflozin (high dose qd), empagliflozin (high dose bid)
- Where
- 139 sites in United States, Australia and 16 more
- Volunteers
- 983 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Confirmatory Study of MT-2412 in Japanese Patients With Type 2 Diabetes (Add-on Study of Canagliflozin)
The purpose of this study is to evaluate the efficacy and safety of co-administration of Teneligliptin (MP-513) and Canagliflozin (TA-7284) once daily for 24 weeks in Japanese patients with Type 2 diabetes mellitus who are…
- Trial name
- NCT02354235
- Testing
- Teneligliptin, Canagliflozin
- Where
- 3 sites in Japan
- Volunteers
- 138 people
- Sponsor
- Tanabe Pharma Corporation
Gout
Allopurinol Combination Study
To compare the proportion of subjects whose serum urate (sUA) levels are < 6.0 mg/dL following 4 weeks of continuous treatment of RDEA594 in combination with allopurinol to allopurinol alone in subjects with documented inadequate…
- Trial name
- RDEA594-203 (NCT01001338)
- Testing
- RDEA594, Allopurinol
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 227 people
- Sponsor
- Ardea Biosciences, Inc.
Diabetes Mellitus, Type 2
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
- Trial name
- NCT00283049
- Testing
- Insulin Glargine, Insulin Glulisine
- Where
- United States
- Volunteers
- 390 people
- Sponsor
- Sanofi
Diabetes Mellitus
ALPHA Sitagliptin Add on to Metformin (0431-103)
Canadian physicians to experience in real life clinical practice the efficacy and tolerability of adding sitagliptin to their patients who have their glycemic levels inadequately controlled while on metformin
- Trial name
- NCT00833027
- Testing
- sitagliptin phosphate
- Volunteers
- 608 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies
The study is a comparison of twice-daily insulin lispro low mixture versus once-daily basal insulin glargine and once-daily prandial insulin lispro, in participants with Type 2 Diabetes.
- Trial name
- NCT01175824
- Testing
- Insulin Lispro Low Mixture (LM), Insulin Glargine, Prandial Insulin Lispro
- Where
- 18 sites in Argentina, Brazil and 6 more
- Volunteers
- 478 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Comprehensive add-on Study in Japanese Subjects With Type 2 Diabetes Mellitus
The objective of the study is to investigate the long-term safety and efficacy of BI 10773 given for 52 weeks as add-on therapy to one oral antidiabetic drug in patients with type 2 diabetes mellitus with insufficient glycaemic…
- Trial name
- NCT01368081
- Testing
- Metformin, BI 10773
- Where
- 87 sites in Japan
- Volunteers
- 1,162 people
- Sponsor
- Boehringer Ingelheim
T2DM (Type 2 Diabetes Mellitus)
A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus
This double-masked placebo-controlled study will include approximately 450 subjects with inadequately controlled T2DM on diet control alone or on diet control and metformin monotherapy.
- Trial name
- NCT04754334
- Testing
- ORMD-0801
- Where
- United States
- Volunteers
- 346 people
- Sponsor
- Oramed, Ltd.
Diabetes Mellitus, Type 2
Efficacy and Safety Study of Linagliptin (5 mg Administered Orally Once Daily) Over 24 Weeks, in Drug naïve or Previously Treated Type 2 Diabetic Patients With Insufficient Glycaemic Control
In this randomised, double-blind, parallel group trial, the safety and efficacy of 5 mg of Linagliptin administered orally once daily will be compared with a placebo after 24 weeks of treatment in monotherapy in patients with…
- Trial name
- NCT01214239
- Testing
- Linagliptin
- Where
- 19 sites in China, Malaysia and 1 more
- Volunteers
- 300 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study to Evaluate the Efficacy and Safety of Gemigliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Dapagliflozin and Metformin (SOLUTION Study)
The objective of this study is to evaluate the efficacy and safety of gemigliptin 50 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic…
- Trial name
- NCT03842267
- Testing
- Gemigliptin 50mg
- Where
- South Korea
- Volunteers
- 315 people
- Sponsor
- LG Chem
Diabetes Mellitus, Type 2
Efficacy vs Placebo as Initial Combination Therapy With Pioglitazone
The objective of the current study is to investigate the efficacy, safety and tolerability of BI 1356 (Linagliptin) (5 mg / once daily) compared to placebo given for 24 weeks as initial combination therapy with pioglitazone 30 mg…
- Trial name
- NCT00641043
- Testing
- Linagliptin + pioglitazone (30 mg)
- Where
- 43 sites in Austria, Greece and 5 more
- Volunteers
- 389 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus
Efficacy of Alogliptin and Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of the study is to compare the effect of adding alogliptin, once daily (QD), to the ongoing treatment regimen of pioglitazone HCl and metformin in patients with inadequate glycemic control.
- Trial name
- NCT00432276
- Testing
- Alogliptin, Pioglitazone, Metformin
- Where
- 86 sites in United States
- Volunteers
- 803 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus
A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)
A study to assess the safety and efficacy of MK8245 as monotherapy compared to placebo.
- Trial name
- NCT00846391
- Testing
- MK8245 5 mg (twice a day) b.i.d., MK8245 50 mg b.i.d.
- Volunteers
- 14 people
- Sponsor
- Merck Sharp & Dohme LLC